onr:"swepub:oai:DiVA.org:liu-116549"
Search: onr:"swepub:oai:DiVA.org:liu-116549" > Mangafodipir as a c...
- 1 of 1
- Previous record
- Next record
- To hitlist
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04788naa a2200445 4500 | |
| 001 | oai:DiVA.org:liu-116549 | |
| 003 | SwePub | |
| 008 | 150327s2015 | |||||||||||000 ||eng| | |
| 009 | oai:prod.swepub.kib.ki.se:227533964 | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1165492 URI |
| 024 | 7 | a https://doi.org/10.1093/ehjcvp/pvu0212 DOI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:2275339642 URI |
| 040 | a (SwePub)liud (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Karlsson, Jan-Eriku Linköpings universitet,Avdelningen för kardiovaskulär medicin,Hälsouniversitetet,Department of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping, Sweden4 aut0 (Swepub:liu)janka97 |
| 245 | 1 0 | a Mangafodipir as a cardioprotective adjunct to reperfusion therapy: a feasibility study in patients with ST-segment elevation myocardial infarction |
| 264 | c 2015-01-01 | |
| 264 | 1 | b European Society of Cardiology,c 2015 |
| 338 | a print2 rdacarrier | |
| 520 | a Aims The aim of the present study was to examine the feasibility of applying the catalytic antioxidant mangafodipir [MnDPDP, manganese (Mn) dipyridoxyl diphosphate] as a cardioprotective adjunct to primary percutaneous coronary intervention (pPCI) in patients with ST-segment elevation (STE) myocardial infarction (STEMI). Both MnDPDP and a metabolite (Mn dipyridoxyl ethyldiamine) possess properties as mitochondrial superoxide dismutase mimetics and iron chelators, and combat oxidative stress in various tissues and conditions.Methods and resultsThe study tested MnDPDP (n ¼ 10) vs. saline placebo (n ¼ 10), given as a brief intravenous (i.v.) infusion prior to balloon inflation during pPCI in patients with STEMI. Mangafodipir waswell tolerated and did not affect heart rate or blood pressure. Despite longer ischaemic time (205 vs. 144 min, P ¼ 0.019) in theMnDPDPgroup, plasma biomarker releaseswere identical for the two groups. With placebo vs.MnDPDP, mean STE resolutions were 69.8 vs. 81.9% (P ¼ 0.224) at 6 h and 73.1 vs. 84.3% (P ¼ 0.077) at 48 h. Cardiac magnetic resonance revealed mean infarct sizes of 32.5 vs. 26.2% (P ¼ 0.406) andmeanleft ventricular (LV) ejection fractions of 41.8 vs. 47.7% (P ¼ 0.617) with placebovs.MnDPDP.More LVthrombi were detected in placebo hearts (5 of 8) than MnDPDP-treated hearts (1 of 10; P ¼ 0.011).Conclusions Mangafodipir is a safe drug for use as an adjunct to reperfusion therapy. A tendency to benefit of MnDPDP needs confirmation in a larger population. The study revealed important information for the design of a Phase II trial. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
| 653 | a Cardiac reperfusion injury; Primary PCI; STEMI; Oxidative stress; Mitochondrial superoxide dismutase | |
| 700 | 1 | a El-Saadi, Walidu Department of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping, Sweden4 aut |
| 700 | 1 | a Ali, Mustafau Department of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping, Sweden; Department of Radiology, County Council of Jönköping, Jönköping, Sweden4 aut |
| 700 | 1 | a Puskar, Werneru Department of Radiology, County Council of Jönköping, Jönköping, Sweden4 aut |
| 700 | 1 | a Skogvard, Patriku Department of Internal Medicine, County Council of Jönköping, Ryhov County Hospital, Jönköping, Sweden4 aut |
| 700 | 1 | a Engvall, Jan Eu Östergötlands Läns Landsting,Linköpings universitet,Avdelningen för kardiovaskulär medicin,Hälsouniversitetet,Fysiologiska kliniken US4 aut0 (Swepub:liu)janen74 |
| 700 | 1 | a Andersson, Rolfu Linköpings universitet,Avdelningen för läkemedelsforskning,Hälsouniversitetet4 aut0 (Swepub:liu)rolan40 |
| 700 | 1 | a Maret, Evau Karolinska Institutet4 aut |
| 700 | 1 | a Jynge, Peru Linköpings universitet,Avdelningen för läkemedelsforskning,Hälsouniversitetet,PledPharma AB, Stockholm, Sweden4 aut0 (Swepub:liu)perjy52 |
| 710 | 2 | a Linköpings universitetb Avdelningen för kardiovaskulär medicin4 org |
| 773 | 0 | t European Heart Journal - Cardiovascular Pharmacotherapyd : European Society of Cardiologyg 1:1, s. 39-45q 1:1<39-45x 2055-6837x 2055-6845 |
| 856 | 4 | u https://academic.oup.com/ehjcvp/article-pdf/1/1/39/8066482/pvu021.pdf |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-116549 |
| 856 | 4 8 | u https://doi.org/10.1093/ehjcvp/pvu021 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:227533964 |
Find in a library
- European Heart Journal - Cardiovascular Pharmacotherapy (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Karlsson, Jan-Er ...
- El-Saadi, Walid
- Ali, Mustafa
- Puskar, Werner
- Skogvard, Patrik
- Engvall, Jan E
- show more...
- Andersson, Rolf
- Maret, Eva
- Jynge, Per
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cardiac and Card ...
- Articles in the publication
- European Heart J ...
- By the university
- Linköping University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
